Showing results (401-410 of 909) with videos related to

Sort By:
Pageof 91
Stroke|January 29, 2015
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failureRoopinder K Sandhu, Stefan H Hohnloser, Marc A Pfeffer, et al.
The American Journal of Cardiology|July 7, 2009
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial)Robert M Califf, Yuliya Lokhnygina, Eric J Velazquez, et al.
American Heart Journal|March 29, 2008
Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndromeLisa M Mielniczuk, Marc A Pfeffer, Eldrin F Lewis, et al.
European Journal of Heart Failure|December 2, 2017
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failureEmil Wolsk, Brian Claggett, Lars Køber, et al.
European Journal of Heart Failure|July 19, 2016
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programmeKevin Damman, Scott D Solomon, Marc A Pfeffer, et al.
JAMA|September 18, 2003
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trialChristopher M O'Connor, Michael W Dunne, Marc A Pfeffer, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
Circulation|June 28, 2006
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trialScott D Solomon, Madeline M Rice, Kathleen A Jablonski, et al.
The New England Journal of Medicine|February 17, 2005
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionScott D Solomon, John J V McMurray, Marc A Pfeffer, et al.
European Heart Journal|November 7, 2008
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programmeAlain Cohen-Solal, John J V McMurray, Karl Swedberg, et al.
Pageof 91